Astrazeneca Says Late-Stage Trial of Rare Kidney Disease Treatment Meets Primary Endpoint
Idag, 11:06
05:06 AM EDT, 04/21/2026 (MT Newswires) -- AstraZeneca (AZN) said Tuesday a phase 3 trial of Ultomiris in adults with Immunoglobulin A nephropathy, a rare kidney disease, met its primary endpoint.
The study showed a statistically significant reduction in proteinuria, based on 24-hour urine protein creatinine ratio at week 34, the company said.
AstraZeneca said it plans to submit the data to regulatory authorities while continuing the trial.
Ämnen i artikeln
Astrazeneca Says Late-Stage Trial of Rare Kidney Disease Treatment Meets Primary Endpoint
Idag, 11:06
05:06 AM EDT, 04/21/2026 (MT Newswires) -- AstraZeneca (AZN) said Tuesday a phase 3 trial of Ultomiris in adults with Immunoglobulin A nephropathy, a rare kidney disease, met its primary endpoint.
The study showed a statistically significant reduction in proteinuria, based on 24-hour urine protein creatinine ratio at week 34, the company said.
AstraZeneca said it plans to submit the data to regulatory authorities while continuing the trial.
Ämnen i artikeln
Rapporter
Banker
Analys
Rapporter
Banker
Analys
Marknadsöversikt
1 DAG %
Senast
1 mån
